EyeLief™

EyeLief™

EyeLief™ implant is a novel sustained-release photocrosslinked preformed biodegradable implant which can sustain release of therapeutics for 4-6 months or more.

 

Size of the EyeLief™ implants compared to the British five-pence coin.

Microscopic Image of Implant

Advantages of EyeLief™

  • Simple fabrication technique
  • Safe and non-toxic to ocular tissues
  • Can be surgically implanted or injected directly in the eye
  • Sustained drug delivery of small molecules and proteins is achievable for 4-6 months or more
  • High % loading of both small and large molecules
  • Controlled burst release and tailored release profiles are achievable

CONTACT US

United Kingdom
T: +44 (0) 28 9097 5814
E: info@re-vana.com

USA

T: +1 (813) 323 1438
E: mor.revana@gmail.com

Mailing
Re-Vana Therapeutics Ltd 
McClay Research Centre
97 Lisburn Road
Belfast, BT9 7BL
United Kingdom

Re-Vana Therapeutics Inc.
1027 South Dakota Ave
Tampa, FL 33606
USA

OPPORTUNITIES


Check back for opportunities.

PARTNERSHIPS

Re-Vana collaborates and is open to business development partnerships to deliver both small and large molecules with our technology platforms.

To discuss please contact Michael O’Rourke CEO on (+1) 813 323 1438  (Tampa Florida) or mor.revana@gmail.com

Our Products

EyeLief™

EyeLief™ is a novel photocrosslinked sustained-release preformed biodegradable implant delivering large and small therapeutics for 4-6 months or more.

OcuLief™

OcuLief™ is a novel photocrosslinked biodegradable gel implant for the sustained release of large and small therapeutics for 4-6 months or more.

NICOX ENTERS RESEARCH COLLABORATION WITH RE-VANA THERAPEUTICS

Re-Vana's technology offers us additional opportunities, alongside our recently announced collaboration with pSivida, to explore the potential for sustained-release delivery of our novel, next generation of stand-alone NO-donors. EyeLief(TM) technology has a number of unique properties that have shown promise in the delivery of drugs for the reduction of IOP. We look forward to working with Re-Vana on this innovative research endeavor.
Michael Bergamini, Executive Vice President and Chief Scientific Officer, Nicox

RE-VANA'S DESIGN STRATEGY

The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.

CONTACT US

United Kingdom
T: +44 (0) 28 9097 5814
E: info@re-vana.com

USA

T: +1 (813) 323 1438
E: mor.revana@gmail.com

Mailing

Re-Vana Therapeutics Ltd
McClay Research Centre
97 Lisburn Road
Belfast, BT9 7BL
United Kingdom

Re-Vana Therapeutics Inc.
1027 South Dakota Ave
Tampa, FL 33606
USA